Baxter pays $100m upfront for ex-US rights to pancreatic cancer candidate
This article was originally published in Scrip
Executive Summary
Baxter is to pay $100m upfront for ex-US rights (excluding Taiwan) for Merrimack Pharmaceuticals' MM-398 (nanoliposomal irinotecan injection), also known as nal-IRI, a drug candidate for pancreatic cancer.